GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (FRA:G28) » Definitions » YoY EBITDA Growth

Tevogen Bio Holdings (FRA:G28) YoY EBITDA Growth : -179.73% (As of Mar. 2025)


View and export this data going back to 2024. Start your Free Trial

What is Tevogen Bio Holdings YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Tevogen Bio Holdings's YoY EBITDA Growth for the quarter that ended in Mar. 2025 was -179.73%.

Tevogen Bio Holdings's EBITDA per Share for the three months ended in Mar. 2025 was €-0.06.

Tevogen Bio Holdings YoY EBITDA Growth Historical Data

The historical data trend for Tevogen Bio Holdings's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tevogen Bio Holdings YoY EBITDA Growth Chart

Tevogen Bio Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24
YoY EBITDA Growth
- 131.53 -1,031.43 73.62

Tevogen Bio Holdings Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 131.36 -300.00 -50.00 -366.67 -179.73

Tevogen Bio Holdings YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Tevogen Bio Holdings's YoY EBITDA Growth for the fiscal year that ended in Dec. 2024 is calculated as:

YoY EBITDA Growth (A: Dec. 2024 )
=(EBITDA per Share (A: Dec. 2024 )-EBITDA per Share (A: Dec. 2023 ))/ | EBITDA per Share (A: Dec. 2023 ) |
=(-0.086--0.326)/ | -0.326 |
=73.62 %

Tevogen Bio Holdings's YoY EBITDA Growth for the quarter that ended in Mar. 2025 is calculated as:

YoY EBITDA Growth (Q: Mar. 2025 )
=(EBITDA per Share (Q: Mar. 2025 )-EBITDA per Share (Q: Mar. 2024 )) / | EBITDA per Share (Q: Mar. 2024 )) |
=(-0.059-0.074)/ | 0.074 |
=-179.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tevogen Bio Holdings YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Tevogen Bio Holdings's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Tevogen Bio Holdings Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tevogen Bio Holdings Inc (FRA:G28) » Definitions » YoY EBITDA Growth
Comparable Companies
RGLS INMB YMAB DRTS HURA CDXS INBX SGMO TVRD ACTU VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
TVGN:USA
Address
15 Independence Boulevard, Warren, NJ, USA, 07059
Website
https://www.tevogen.com
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.

Tevogen Bio Holdings Headlines

No Headlines